Conditions: Advanced Breast Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 52
Healthy volunteers: no

Brief summary:
The purpose of this study is to learn about the safety and efficacy of Dasatinib in combination with Capecitabine for patients with advanced breast cancer, and who have received treatment with a taxane and an anthracycline

Detailed description:

Arms:
arm 1: Twice a day (BID) for 2 weeks of a 3-week cycle arm 2: BID for 2 weeks of a 3-week cycle arm 3: BID for 2 weeks of a 3-week cycle arm 4: 2 weeks of a 3-week cycle

Interventions: intervention 1: Dasatinib intervention 2: Capecitabine
Intervention descriptions: intervention 1: Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression intervention 2: Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.

Protocol document: